Stockscreener 앱 받기
11.99
0.99%
-0.12
시간 외 거래:
12.11
0.12
+1.00%
전일 마감가:
$12.11
열려 있는:
$12.12
하루 거래량:
666.84K
Relative Volume:
1.08
시가총액:
$759.22M
수익:
$202.09M
순이익/손실:
$-61.69M
주가수익비율:
-10.25
EPS:
-1.17
순현금흐름:
$-35.64M
1주 성능:
-8.61%
1개월 성능:
-27.86%
6개월 성능:
-11.77%
1년 성능:
+27.83%
1일 변동 폭
$11.95
$12.67
1주일 범위
$11.37
$13.05
52주 변동 폭
$9.24
$17.82
Evolus Inc Stock (EOLS) Company Profile
명칭
Evolus Inc
전화
(949) 284-4555
주소
520 NEWPORT CENTER DRIVE, NEWPORT BEACH
EOLS을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
| EOLS | 11.99 | 759.22M | 202.09M | -61.69M | -35.64M | -1.17 |
| ZTS | 176.42 | 79.51B | 9.15B | 2.43B | 2.31B | 4.92 |
| TAK | 13.53 | 42.89B | 30.27B | 1.93B | 3.45B | 0.444 |
| HLN | 9.43 | 42.57B | 14.26B | 1.55B | 0 | 0.3327 |
| TEVA | 16.49 | 18.51B | 16.77B | -959.00M | 1.37B | -2.00 |
| VTRS | 13.00 | 15.37B | 15.24B | -646.50M | 1.88B | 1.53 |
Evolus Inc Stock (EOLS) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2024-01-29 | 업그레이드 | Barclays | Equal Weight → Overweight |
| 2022-06-23 | 개시 | Needham | Buy |
| 2022-05-12 | 업그레이드 | Barclays | Underweight → Equal Weight |
| 2022-01-20 | 업그레이드 | Truist | Hold → Buy |
| 2021-05-06 | 업그레이드 | Mizuho | Neutral → Buy |
| 2021-04-08 | 재확인 | H.C. Wainwright | Buy |
| 2021-02-24 | 다운그레이드 | Truist | Buy → Hold |
| 2020-07-07 | 다운그레이드 | Mizuho | Buy → Neutral |
| 2020-02-06 | 재개 | Mizuho | Buy |
| 2019-11-26 | 개시 | SVB Leerink | Outperform |
| 2019-09-05 | 재개 | Mizuho | Buy |
| 2019-06-28 | 개시 | Wells Fargo | Market Perform |
| 2019-06-11 | 개시 | Barclays | Underweight |
| 2019-03-20 | 개시 | SunTrust | Buy |
| 2019-02-14 | 개시 | H.C. Wainwright | Buy |
| 2019-01-29 | 개시 | Stifel | Buy |
모두보기
Evolus Inc 주식(EOLS)의 최신 뉴스
Here's Why Evolus (EOLS) Could be Great Choice for a Bottom Fisher - Zacks Investment Research
Evolus, Inc. (NASDAQ:EOLS) Short Interest Up 8.8% in October - MarketBeat
OC500 2024: Sandra Beaver - Orange County Business Journal
Behind the Bell: Evolus - Nasdaq
Perceptive Advisors LLC Adjusts Stake in Evolus Inc - GuruFocus.com
Down -29.8% in 4 Weeks, Here's Why You Should You Buy the Dip in Evolus (EOLS) - Yahoo Finance
Stonepine Capital Management Reduces Stake in Evolus Inc - GuruFocus.com
Evolus, Inc. (NASDAQ:EOLS) Might Not Be As Mispriced As It Looks After Plunging 26% - Simply Wall St
Evolus, Inc. (NASDAQ:EOLS) Position Increased by GSA Capital Partners LLP - MarketBeat
Evolus's SWOT analysis: medical aesthetics firm's stock poised for growth - Investing.com India
Evolus Inc (EOLS) Shares Gap Down to $12.58 on Nov 12 - GuruFocus.com
Evolus Third Quarter 2024 Earnings: Misses Expectations - Simply Wall St
Evolus, Inc. (EOLS) Reports Q3 Loss, Misses Revenue Estimates - MSN
Earnings Update: Evolus, Inc. (NASDAQ:EOLS) Just Reported Its Third-Quarter Results And Analysts Are Updating Their Forecasts - Yahoo Finance
Evolus, Inc. (NASDAQ:EOLS) Q3 2024 Earnings Call Transcript - Insider Monkey
Evolus Inc (EOLS) Q3 2024 Earnings Call Highlights: Revenue Surge Amid Market Challenges By GuruFocus - Investing.com Canada
Evolus (NASDAQ:EOLS) Shares Gap Down on Disappointing Earnings - MarketBeat
Evolus' (EOLS) Buy Rating Reiterated at HC Wainwright - MarketBeat
Evolus Inc (EOLS) Q3 2024 Earnings Call Highlights: Revenue Surge Amid Market Challenges - GuruFocus.com
Evolus earnings missed by $0.18, revenue fell short of estimates - Investing.com Canada
Evolus, Inc. Reports Strong Q3 2024 Growth - TipRanks
Evolus Reports Third Quarter 2024 Results - Business Wire
Injections For Your Frown Lines Cost Just $49, Thanks To This Membership Club - The Zoe Report
Prescription Hair Loss and Hair Removal Drugs Market Projected To Witness Substantial Growth, 2024-2031: - EIN News
Evolus (NASDAQ:EOLS) Earns "Buy" Rating from HC Wainwright - MarketBeat
Evolus to Participate in Stifel 2024 Healthcare Conference - The Bakersfield Californian
Evolus, Inc. (NASDAQ:EOLS) Shares Purchased by Rice Hall James & Associates LLC - MarketBeat
Objective long/short (EOLS) Report - Stock Traders Daily
Evolus, Inc. Announces EU Approval of Estyme Injectable Hyaluronic Acid Gels Under New Medical Device Regulation - Marketscreener.com
Evolus Gets EU Approval for Treatment of Wrinkles - MarketWatch
Evolus gains EU certification for new dermal filler products - Investing.com
Evolus gains EU certification for new dermal filler products By Investing.com - Investing.com UK
Will Evolus, Inc. (EOLS) Report Negative Earnings Next Week? What You Should Know - MSN
Evolus Announces EU Approval of Estyme® Injectable Hyaluronic Acid Gels Under New Medical Device Regulation - StockTitan
Evolus (EOLS) Scheduled to Post Quarterly Earnings on Wednesday - MarketBeat
Evolus Rewards™ Patient Loyalty Program Surpasses 1 Million Enrolled Consumers - Business Wire
Semanteon Capital Management LP Purchases Shares of 56,313 Evolus, Inc. (NASDAQ:EOLS) - MarketBeat
Evolus Inc (EOLS) Trading 3.55% Higher on Oct 25 - GuruFocus.com
Evolus to Report Third Quarter Financial Results on November 6, 2024 - Business Wire
First Week of December 20th Options Trading For Evolus (EOLS) - Nasdaq
Does Evolus (NASDAQ:EOLS) Have A Healthy Balance Sheet? - Simply Wall St
When the Price of (EOLS) Talks, People Listen - Stock Traders Daily
Evolus (NASDAQ:EOLS) Shares Down 6.2%Here's Why - MarketBeat
Evolus Inc (EOLS) Stock Price Down 4.81% on Oct 17 - GuruFocus.com
Evolus Inc (EOLS) receives an Overweight rating from Barclays - Knox Daily
SG Americas Securities LLC Makes New $623,000 Investment in Evolus, Inc. (NASDAQ:EOLS) - MarketBeat
Evolus (NASDAQ:EOLS) Hits New 1-Year HighTime to Buy? - MarketBeat
Evolus stock soars to 52-week high, hits $17.75 - Investing.com India
Evolus stock soars to 52-week high, hits $17.75 By Investing.com - Investing.com UK
Evolus Inc (EOLS) Trading 3.55% Higher on Oct 14 - GuruFocus.com
Evolus Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)October 12, 2024 - BioSpace
Evolus Inc (EOLS) 재무 분석
매출
순이익
현금흐름
주당 순 이익
0.79%
0.15%
자본화:
|
볼륨(24시간):